PlushCare review

PlushCare’s advertised starting price is a membership fee, not an all-inclusive GLP-1 package. The official site lists a 30-day free trial followed by $19.99 per month, or an annual membership costing $149. Membership benefits include appointment booking, care-team messaging, prescription-renewal requests, a prescription discount card, discounted laboratory testing, and memberships for family members. Physician appointments remain separately billable. With insurance, the patient pays the applicable copay or other plan-determined amount; PlushCare says many in-network patients pay $30 or less, but it identifies this only as a common result rather than a guarantee. The published cash price for new members is $129 per visit. Medication and laboratory work are expressly excluded. PlushCare says branded GLP-1 drugs without coverage can cost roughly $1,000 monthly, but actual prices can differ substantially by product, pharmacy, insurance benefits, and manufacturer programs. Follow-up appointments can also add recurring costs. Therefore, $19.99 is an appropriate published monthly starting figure for membership, but it should never be presented as the complete cost of treatment. Patients need an itemized estimate covering membership, expected appointments, labs, and the exact medication before comparing PlushCare with bundled programs.

PlushCare’s current GLP-1 pages emphasize prescriptions selected by a physician rather than one guaranteed product. The site identifies Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) as FDA-approved weight-loss medications. It also discusses Ozempic and Mounjaro, but their FDA-approved indications are for type 2 diabetes, not weight loss; insurers commonly require evidence of that diagnosis before covering them. PlushCare also maintains pages for compounded semaglutide and tirzepatide. Those pages clearly state that compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or manufacturing quality. More importantly, PlushCare says its compounded versions can only be offered through the published shortage pathway while the corresponding brands remain on FDA’s shortage list. FDA currently states that the semaglutide and tirzepatide injection shortages are resolved and that neither substance is presently on its shortage list. Based on PlushCare’s own condition, readers should not assume its displayed compounded prices represent currently purchasable options. The practical model in July 2026 should be treated as FDA-approved brand prescribing, subject to clinician judgment and availability, unless PlushCare documents a lawful patient-specific compounding basis. Any proposed product should be verified by exact name, manufacturer or compounding pharmacy, FDA status, and intended indication.

PlushCare describes a physician-led process delivered through video visits. During the first appointment, a doctor reviews medical history, previous weight-management efforts, current medications, underlying conditions, and treatment goals. The official program page says laboratory work is often required; its GLP-1 page describes an obesity panel that can include blood count, metabolic function, lipids, A1C, thyroid testing, and insulin. The doctor then reviews the results and discusses treatment options during a subsequent visit. A prescription is issued only when the clinician finds it medically appropriate and may be sent to the patient’s selected local pharmacy. PlushCare says its care team can prepare prior-authorization requests for injectable weight-loss and diabetes medications. That administrative help does not ensure approval, and the insurer’s pharmacy-benefit manager makes the coverage decision. PlushCare’s semaglutide page says patients generally meet with their doctor monthly while treatment is being adjusted and lifestyle routines are being developed. Because visits are not included in membership, that cadence can materially affect total cost. Membership includes unlimited messaging with the care team, but it should not be interpreted as unlimited physician consultations. PlushCare says it is fully licensed to provide care in all 50 states, while also warning that not every FDA-approved medication is available in every location.

Before enrolling, request a written estimate separating membership, initial consultation, anticipated follow-ups, laboratory charges, and medication. Confirm when the 30-day trial ends, how cancellation works, and whether PlushCare’s limited-access option without a paid membership can be used for weight-management care. Patients using insurance should verify that PlushCare and the selected physician are in network, then contact the pharmacy-benefit manager about the exact drug and diagnosis. Questions should cover formulary status, prior authorization, step therapy, deductibles, copays, and whether weight-loss medication is excluded altogether. PlushCare can submit prior-authorization documentation, but coverage remains uncertain until the insurer issues a decision. For cash purchases, obtain the current price from the dispensing pharmacy or manufacturer program rather than relying on PlushCare’s approximate brand-cost statement. If a compounded product is proposed, ask for the pharmacy’s legal name, state license, 503A or 503B status, formulation, and the documented reason compounding is permissible despite resolved national shortages. Verify that information against FDA’s current shortage and compounding guidance. PlushCare’s compound pages publish state-specific lists, but those lists do not override the shortage condition and may become outdated. Finally, confirm that the prescription record identifies whether the dispensed item is an FDA-approved manufacturer product or a non-FDA-approved compound.

PlushCare may fit adults who want an ongoing relationship with a primary-care physician, prefer video appointments, and are prepared to use insurance or compare pharmacy options for an FDA-approved medication. Its nationwide care footprint, same-day appointment availability, care-team messaging, and prior-authorization assistance are useful for patients who value clinical access more than a single bundled price. It can also make sense when the patient wants a clinician who can address health issues beyond weight management. It is less suitable for someone seeking a predictable, medication-included subscription. The headline membership price excludes every physician visit, laboratory work, and the medication itself, while monthly follow-ups may be needed during treatment changes. It also does not fit anyone expecting a guaranteed GLP-1 prescription or guaranteed insurance coverage: the clinician may recommend lifestyle support, a non-GLP-1 medication, or no prescription, and the insurer may deny authorization. People who want only an FDA-approved brand should confirm the exact product before paying. Those specifically shopping for inexpensive compounded semaglutide or tirzepatide should be especially cautious because PlushCare’s published offer is conditional on national shortages that FDA currently considers resolved. Overall value depends on the patient’s insurance benefits, follow-up frequency, required labs, and final pharmacy price—not on the membership fee alone.